摘要
目的 观察并评价低剂量白细胞介素11（IL-11）治疗恶性血液病化疗后血小板减少的临床疗效.方法 将70例化疗后伴血小板减少的恶性血液病（包括急性白血病、淋巴瘤、多发性骨髓瘤）患者随机分为治疗组和对照组,各35例.治疗组患者在化疗结束24 h后开始按50μg·kg-1·d-1剂量给予IL-11皮下注射,连续应用直至血小板数≥50×109/L.对照组患者化疗后则不予IL-11治疗.结果 治疗组血小板数恢复至≥50×109/L的平均时间为9.6 d,明显短于对照组（14.0 d,P＜0.05）;血小板最低值平均为16.2×109/L,明显高于对照组（11.6×109/L,P＜0.05）;血小板输注平均次数为2.88次,与对照组（2.98次）比较,差异无统计学意义（P＞0.05）.治疗组中,有1例急性白血病患者诉心悸,有2例急性白血病和1例淋巴瘤患者出现畏寒、肌肉酸痛、乏力,但均能耐受.结论 应用IL-11治疗恶性血液病化疗后血小板减少,不仅能明显提高患者的血小板数和血小板最低水平,缩短血小板的恢复时间,而且不良反应轻微.
Objective To investigate and evaluate the clinical therapeutic effect of low-dose interleukin-11 treatment of thrombocytopenia in patients with malignant hematologic diseases after chemotherapy. Methods 70 patients with hematologic malignancies including acute leukemia, lymphoma and multiple myeloma were randomly divided into treatment group （35 cases） and control group （35 cases）and were treated with chemotherapy. Cases in the treatment group received subcutaneous injection of control group were not administrated with interleukin-11. （50 μg·kg-1·d-1） until platelet counting recovered ≥50 × 109/L, while cases in the control group were not administrated with interleukin-11.Results The mean time of platelet recovery in the treatment group was 9.6 days, significantly shorter than that （14.0 days） in the control group （P 〈 0. 05）.The minimum platelet counting in the treatment group was significantly higher than that in the control group （16.2 × 109/L vs. 11.6 × 109/L, P 〈 0.05）. The mean times of platelet infusion after chemotherapy in the treatment group and control group were 2.88 and 2.98, respectively （P〉0.05）. Conclusion Administration of interleukin-11 in thrombocytopenic patients with hematologic malignancies after chemotherapy may not only remarkably enhance platelet counts and shorten the recovery time of thrombocytopenia, but also has only mild side effects.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2010年第9期713-715,共3页
Chinese Journal of Oncology
关键词
白细胞介素11
血液肿瘤
血小板减少
化疗
Interleukin-11
Hematologic neoplasms
Thrombocytopenia
Chemotherapy
